306 related articles for article (PubMed ID: 18927302)
21. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
22. A novel approach to using matrix metalloproteinases for bladder cancer.
Fernández CA; Wszolek MF; Loughlin KR; Libertino JA; Summerhayes IC; Shuber AP
J Urol; 2009 Nov; 182(5):2188-94. PubMed ID: 19758628
[TBL] [Abstract][Full Text] [Related]
23. Urine biomarkers may someday detect even distant tumors.
Schmidt C
J Natl Cancer Inst; 2009 Jan; 101(1):8-10. PubMed ID: 19116386
[No Abstract] [Full Text] [Related]
24. Prenatal urinary matrix metalloproteinase profiling as a potential diagnostic tool in fetal obstructive uropathy.
Nicksa GA; Yu DC; Curatolo AS; McNeish BL; Barnewolt CE; Valim C; Buchmiller TL; Moses MA; Fauza DO
J Pediatr Surg; 2010 Jan; 45(1):70-3. PubMed ID: 20105582
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic value of urinary molecular markers in bladder cancer.
Eissa S; Swellam M; el-Mosallamy H; Mourad MS; Hamdy NΜ; Kamel K; Zaglol AS; Khafagy MM; el-Ahmady O
Anticancer Res; 2003; 23(5b):4347-55. PubMed ID: 14666650
[TBL] [Abstract][Full Text] [Related]
26. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease.
Fitzsimmons PJ; Forough R; Lawrence ME; Gantt DS; Rajab MH; Kim H; Weylie B; Spiekerman AM; Dehmer GJ
Atherosclerosis; 2007 Sep; 194(1):196-203. PubMed ID: 16942771
[TBL] [Abstract][Full Text] [Related]
27. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment.
Pories SE; Zurakowski D; Roy R; Lamb CC; Raza S; Exarhopoulos A; Scheib RG; Schumer S; Lenahan C; Borges V; Louis GW; Anand A; Isakovich N; Hirshfield-Bartek J; Wewer U; Lotz MM; Moses MA
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1034-42. PubMed ID: 18483323
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine.
Nutt JE; Durkan GC; Mellon JK; Lunec J
BJU Int; 2003 Jan; 91(1):99-104. PubMed ID: 12614260
[TBL] [Abstract][Full Text] [Related]
29. Urinary MMP-9/NGAL ratio as a potential marker of FSGS in nephrotic children.
Korzeniecka-Kozerska A; Wasilewska A; Tenderenda E; Sulik A; Cybulski K
Dis Markers; 2013; 34(5):357-62. PubMed ID: 23478276
[TBL] [Abstract][Full Text] [Related]
30. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
31. Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000.
Gerhards S; Jung K; Koenig F; Daniltchenko D; Hauptmann S; Schnorr D; Loening SA
Clin Cancer Res; 2001 Feb; 7(2):445-7. PubMed ID: 11234903
[No Abstract] [Full Text] [Related]
32. Urinary matrix metalloproteinases and their endogenous inhibitors predict hepatic regeneration after murine partial hepatectomy.
Greene AK; Puder M; Roy R; Kilroy S; Louis G; Folkman J; Moses MA
Transplantation; 2004 Oct; 78(8):1139-44. PubMed ID: 15502710
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
Vasala K; Pääkko P; Turpeenniemi-Hujanen T
Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455
[TBL] [Abstract][Full Text] [Related]
34. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients.
Fernández CA; Yan L; Louis G; Yang J; Kutok JL; Moses MA
Clin Cancer Res; 2005 Aug; 11(15):5390-5. PubMed ID: 16061852
[TBL] [Abstract][Full Text] [Related]
35. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
36. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
37. Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9.
Gupta K; Shukla M; Cowland JB; Malemud CJ; Haqqi TM
Arthritis Rheum; 2007 Oct; 56(10):3326-35. PubMed ID: 17907186
[TBL] [Abstract][Full Text] [Related]
38. Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas.
Monier F; Mollier S; Guillot M; Rambeaud JJ; Morel F; Zaoui P
Eur Urol; 2002 Oct; 42(4):356-63. PubMed ID: 12361901
[TBL] [Abstract][Full Text] [Related]
39. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.
Roy R; Zurakowski D; Wischhusen J; Frauenhoffer C; Hooshmand S; Kulke M; Moses MA
Br J Cancer; 2014 Oct; 111(9):1772-9. PubMed ID: 25137018
[TBL] [Abstract][Full Text] [Related]
40. The biochemical value of urinary metalloproteinases 3 and 9 in diagnosis and prognosis of bladder cancer in Egypt.
El-Sharkawi F; El Sabah M; Hassan Z; Khaled H
J Biomed Sci; 2014 Aug; 21(1):72. PubMed ID: 25135219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
